Aurich Matthias, Hofmann Gunther Olaf, Rolauffs Bernd
Center of Orthopaedic and Trauma Surgery, Klinikum Ingolstadt, Krumenauerstr. 25, 85049, Ingolstadt, Germany.
Department of Trauma, Hand and Reconstructive Surgery, University Hospital Jena, Erlanger Allee 101, 07747, Jena, Germany.
Int Orthop. 2017 Nov;41(11):2327-2335. doi: 10.1007/s00264-017-3615-y. Epub 2017 Aug 21.
The aim was to analyse the biological characteristics of chondrocytes from the two biopsy sites notch vs. trochlea of human knee joints. The question was whether tissue engineering-relevant characteristics such as viability and mRNA expression profile would be comparable ex vivo and after monolayer expansion, as these are parts of routine autologous chondrocyte implantation (ACI).
Biopsies from the intercondylar notch and the lateral aspect of the trochlea from 20 patients with ICRS grades 3 and 4 cartilage defects were harvested during arthroscopy. Collagen types 1, 2, and 10 mRNA were quantified by polymerase chain reaction.
Compared with notch chondrocytes, ex vivo trochlea chondrocytes had comparable cell numbers, vitality and aggrecan, collagen types 1, -2 and -10 mRNA expression. After monolayer expansion both notch and trochlea chondrocyte characteristics were comparably altered, regardless of their biopsy origin, and no significant differences in viability and mRNA expression were noted.
Collectively, these findings suggest that tissue engineering-relevant characteristics of notch and trochlea chondrocytes are comparable ex vivo and after monolayer expansion. Thus, trochlea chondrocytes promise clinical potential and chondrocytes for ACI could potentially be generated from both notch and trochlea biopsy sites.
旨在分析取自人类膝关节两个活检部位（髁间切迹与滑车）的软骨细胞的生物学特性。问题在于与组织工程相关的特性，如活力和mRNA表达谱，在体外及单层扩增后是否具有可比性，因为这些是常规自体软骨细胞植入（ACI）的组成部分。
在关节镜检查期间，从20例国际软骨修复协会（ICRS）3级和4级软骨损伤患者的髁间切迹和滑车外侧获取活检样本。通过聚合酶链反应对1型、2型和10型胶原蛋白mRNA进行定量分析。
与切迹软骨细胞相比，体外滑车软骨细胞在细胞数量、活力以及聚集蛋白聚糖、1型、2型和10型胶原蛋白mRNA表达方面具有可比性。在单层扩增后，无论活检来源如何，切迹和滑车软骨细胞的特性均发生了类似变化，且在活力和mRNA表达方面未发现显著差异。
总体而言，这些发现表明，切迹和滑车软骨细胞与组织工程相关的特性在体外及单层扩增后具有可比性。因此，滑车软骨细胞具有临床应用潜力，并且ACI所需的软骨细胞可能从切迹和滑车活检部位均可获取。
